Nanovery

Executive Summary

Nanovery is a UK-based diagnostics company developing a novel platform technology that leverages DNA nanotechnology to create nanorobotic sensors for precise quantification of nucleic acid sequences. Founded in 2020 and headquartered in London, the company aims to simplify and accelerate molecular diagnostics by offering a quick, cost-effective, and easy-to-use workflow. Their approach promises to reduce the complexity and expense of current nucleic acid testing methods, targeting applications in infectious disease detection and beyond. By employing cutting-edge DNA nanotechnology, Nanovery’s sensors can be tailored to specific targets, potentially enabling earlier and more accurate diagnosis with minimal sample preparation. Although still in its early stages with no disclosed funding or commercial products, Nanovery’s technology holds significant promise for transforming point-of-care diagnostics. The company operates in a competitive landscape dominated by PCR and NGS-based methods, but its unique nanorobotic platform could carve a niche in applications requiring rapid, low-cost quantification. Key challenges include scaling manufacturing, validating clinical performance, and securing regulatory approvals. If successful, Nanovery could address unmet needs in resource-limited settings and decentralized testing. The next 12-18 months will be critical for demonstrating proof-of-concept and attracting investment to advance toward clinical deployment.

Upcoming Catalysts (preview)

• Q4 2026Completion of Proof-of-Concept Studies in Infectious Disease65% success
• Q2 2027Strategic Partnership with Diagnostic OEM or Pharma40% success
• Q1 2027Series A Funding Round Close50% success